Tag: History

PITTSBURGH, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PhyNet Dermatology LLC (“PhyNet”) recently announced a cybersecurity incident involving its affiliate Total Vein & Skin, LLC d/b/a Premier Dermatology Partners (“TVS”), which impacted the personal information of an unknown number of individuals.¹ The information potentially impacted in the data breach includes individuals’ names, addresses, Social Security number, financial account information, date of birth, medical history information, treatment information, diagnosis information, treating physician, medical record number, and health insurance information.

ROCHESTER, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2025 Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 in Boston, MA. The presentation is scheduled to begin at 3:45 p.m. ET and is expected to cover the company’s financial metrics, operating performance, strategic business initiatives, and outlook for the future.

Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA¹ for the Second Quarter and Six Months Ended June 30, 2025 

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.